Patents by Inventor Richard Magous

Richard Magous has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS COMPRISING UROLITHINS AND USES THEREOF FOR THE STIMULATION OF INSULIN SECRETION
    Publication number: 20220096433
    Abstract: The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.
    Type: Application
    Filed: December 13, 2021
    Publication date: March 31, 2022
    Applicants: Centre National de la Recherche Scientifique, Universite de Montpellier, University of Parma, Ecole Nationale Superieure de Chimie de Montpellier
    Inventors: Gérard Cros, Alan Crozier, Margherita Dall'asta, Daniele Del Rio, Richard Magous, Catherine Oiry
  • Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion
    Patent number: 11213508
    Abstract: The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: January 4, 2022
    Assignees: Universite de Montpellier, University de Parma, Ecole Nationale Supérieure de Chimie de Montpellier
    Inventors: Gerard Cros, Alan Crozier, Margherita Dall'asta, Daniele Del Rio, Richard Magous, Catherine Oiry
  • COMPOSITIONS COMPRISING UROLITHINS AND USES THEREOF FOR THE STIMULATION OF INSULIN SECRETION
    Publication number: 20200155504
    Abstract: The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 21, 2020
    Applicants: Centre National de la Recherche Scientifique, Universite de Montpellier, University of Parma, Ecole Nationale Superieure de Chimie
    Inventors: Gerard Cros, Alan Crozier, Margherita Dall'asta, Daniele Del Rio, Richard Magous, Catherine Oiry
  • Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion
    Patent number: 10583114
    Abstract: The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: March 10, 2020
    Assignees: Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier, University of Parma, Ecole Nationale Superieure de Chimie, Centre National de la Recherche Scientifique, Universite de Montpellier
    Inventors: Gerard Cros, Alan Crozier, Margherita Dall'asta, Daniele Del Rio, Richard Magous, Catherine Oiry
  • COMPOSITIONS COMPRISING UROLITHINS AND USES THEREOF FOR THE STIMULATION OF INSULIN SECRETION
    Publication number: 20160279097
    Abstract: The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.
    Type: Application
    Filed: October 15, 2014
    Publication date: September 29, 2016
    Applicants: Centre National de la Recherche Scientifique, Universite de Montpellier, University of Parma, Ecole Nationale Superieure de Chimie
    Inventors: Gerard Cros, Alan Crozier, Margherita Dall'asta, Daniele Del Rio, Richard Magous, Catherine Oiry
  • Reduced peptides which inhibit gastric secretion, process for their preparation and pharmaceutical compositions in which they are present
    Patent number: 4687760
    Abstract: The invention relates to the peptides of the formula: ##STR1## in which: R.sub.1 represents hydrogen or a protecting group for the amine group, such as t-butoxycarbonyl, benzyloxycarbonyl or lower alkanoyl groups;X represents beta-alanine glycine or a direct bond between R.sub.1 and the amine group; andR.sub.2 represents a group chosen from: ##STR2## corresponding to the side chains of the natural amino acid leucine, methionine and norleucine.These peptides inhibit gastric secretion.
    Type: Grant
    Filed: December 16, 1985
    Date of Patent: August 18, 1987
    Assignees: Sanofi, Centre National de la Recherche Scientifque (CNRS)
    Inventors: Jean Martinez, Jean-Pierre Bali, Richard Magous, Bertrand Castro, Henri Demarne
  • Tripeptide and tetrapeptide esters which inhibit gastric secretion, process for their preparation and pharmaceutical compositions in which they are present
    Patent number: 4687759
    Abstract: The invention relates to the peptides of the formula: ##STR1## in which: R represents hydrogen or a protecting group for the terminal amine group, such as t-butoxycarbonyl (Boc), benzyloxycarbonyl (Z) or lower alkanoyl;X.sub.1 represents either beta-Ala or a direct bond between R and the terminal amine group of the amino acid TRP;TRP denotes either the L isomer or the D isomer of tryptophan;X.sub.2 represents L-leucine, L-methionine or L-norleucine; andY denotes hydrogen, a halogen atom (preferably fluorine or chlorine), a trifluoromethyl group, a cyano group or a nitro group.These peptides inhibit gastric secretion.
    Type: Grant
    Filed: December 16, 1985
    Date of Patent: August 18, 1987
    Assignees: Sanofi, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Jean Martinez, Jean-Pierre Bali, Richard Magous, Bertrand Castro, Henri Demarne